{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:25:59Z","timestamp":1793183159177,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Iterum"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40265-022-01688-1","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T07:03:45Z","timestamp":1647414225000},"page":"533-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-0082","authenticated-orcid":false,"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Pozdirca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney K.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Zelenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denice","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph P.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"1688_CR1","unstructured":"Puttagunta S, Aronin S, Gupta V, Murray J, Dunne M. Impact of initial inappropriate antibiotic therapy on outcome for uncomplicated urinary tract infection due to fluoroquinolone non-susceptible Enterobacteriaceae [abstract plus poster]. American Society for Microbiology (ASM) MICROBE 2018. Atlanta, GA; 2018."},{"key":"1688_CR2","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1128\/AAC.00066-11","volume":"55","author":"J Karlowsky","year":"2011","unstructured":"Karlowsky J, Lagac\u00e9-Wiens P, Simner P, DeCorby M, Adam H, Walkty A, et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother. 2011;55:3169\u201375.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR3","unstructured":"Dunne MW, Snow K, Mehta R. Failure of empiric treatment of uncomplicated urinary tract infection (UTI) associated with resistant pathogens [abstract no. 4561 plus poster]. American Society for Microbiology (ASM) MICROBE 2019. San Francisco, CA; 2019."},{"key":"1688_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/00325481.2019.1680052","volume":"132","author":"MS Bader","year":"2020","unstructured":"Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132:234\u201350.","journal-title":"Postgrad Med"},{"key":"1688_CR5","unstructured":"Puttagunta S, Aronin S, Gupta V, Murray J, Dunne M. Impact of initial inappropriate antibiotic therapy on outcome for uncomplicated urinary tract infection due to antibiotic non-susceptible Enterobacteriaceae [abstract plus poster]. American Society for Microbiology (ASM) MICROBE 2018. Atlanta, GA; 2018."},{"key":"1688_CR6","doi-asserted-by":"crossref","unstructured":"Dunne M, Gupta V, Aronin S, Murray J, Puttagunta S. The prevalence of Enterobacteriaceae resistant to all major classes of oral antibiotics from outpatient urine cultures in the United States and effect on clinical outcomes [abstract plus poster]. IDWeek 2018. San Francisco, CA; 2018.","DOI":"10.1093\/ofid\/ofy210.1356"},{"key":"1688_CR7","doi-asserted-by":"crossref","unstructured":"Lagac\u00e9-Wiens P, Simner P, Forward K, Tailor F, Adam. HJ, Decorby M, et al. Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada\u2014results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69:314\u20139.","DOI":"10.1016\/j.diagmicrobio.2010.10.027"},{"key":"1688_CR8","first-page":"e01832","volume":"63","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagac\u00e9-Wiens PRS, Walkty AJ, et al. In vitro activity of sulopenem, an oral penem, against urinary isolates of Escherichia coli. Antimicrob Agents Chemother. 2019;63:e01832-e1918.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR9","unstructured":"Dunne M, Aronin S, Gupta V, Murray J, Puttagunta S. Impact of ESBL-positivity and quinolone non-susceptibility on outcome for inpatients with complicated urinary tract infection: A multicenter evaluation in the U.S. [abstract plus poster]. In: 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid; 2018."},{"key":"1688_CR10","doi-asserted-by":"crossref","unstructured":"Puttagunta S, Gupta V, Murray J, Dunne M. Prevalence of extended spectrum beta-lactamase producing and quinolone non-susceptible Enterobacteriaceae in inpatient and outpatient settings in the USA from 2011-2017 [abstract no. 400 plus poster]. IDWeek 2017. San Diego, CA; 2017.","DOI":"10.1093\/ofid\/ofx163.257"},{"key":"1688_CR11","doi-asserted-by":"publisher","first-page":"vi64","DOI":"10.1093\/jac\/dkz289","volume":"74","author":"AJ Denisuik","year":"2019","unstructured":"Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagac\u00e9-Wiens PRS, Mulvey MR, et al. Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. J Antimicrob Chemother. 2019;74:vi64-71.","journal-title":"J Antimicrob Chemother"},{"key":"1688_CR12","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance. A.R. & Patient Safety Portal. Antibiotic Resistance and Patient Safety Portal. 2019. https:\/\/arpsp.cdc.gov\/profile\/antibiotic-resistance?tab=antibiotic-resistance. Accessed 18 Aug 2021."},{"key":"1688_CR13","doi-asserted-by":"crossref","unstructured":"Dunne MW, Das A, Akinapelli K, Zelasky MT, Boucher HW, Aronin SI. Efficacy and safety of oral sulopenem etzadroxil\/probenecid versus oral ciprofloxacin in the treatment of uncomplicated urinary uract infections (uUTI) in adult women: Results from the SURE-1 trial [abstract plus poster]. IDWeek 2020. Virtual Conference, Online; 2020.","DOI":"10.1093\/ofid\/ofaa515.1898"},{"key":"1688_CR14","doi-asserted-by":"crossref","unstructured":"Dunne M, Aronin S. Efficacy and safety of intravenous sulopenem followed by oral sulopenem etzadroxil\/probenecid versus intravenous ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate in the treatment of complicated urinary tract infections (cUTI): Results from the SURE-2 trial [abstract plus poster]. IDWeek 2020. Virtual Conference, Online; 2020.","DOI":"10.1093\/ofid\/ofaa439.1417"},{"key":"1688_CR15","unstructured":"Chandra R, Hazra A, Skogerboe T, Labadie R, Kirby D, Soma K, et al. Pharmacokinetics (PK), safety and tolerability of single oral doses of PF-03709270, with and without co-administration of probenecid (abstract plus poster F1-353). In: 48th Annual ICAAC\/IDSA 46th Annual Meeting. Washington, DC; 2008."},{"key":"1688_CR16","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1128\/AAC.01557-08","volume":"53","author":"LM Ednie","year":"2009","unstructured":"Ednie LM, Appelbaum PC. Antianaerobic activity of sulopenem compared to six other agents. Antimicrob Agents Chemother. 2009;53:2163\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR17","unstructured":"Dunne M, Huband M, Flamm R, Aronin S, Puttagunta S. Prediction of sulopenem activity against Enterobacteriaceae using ertapenem as a surrogate [abstract plus poster]. American Society for Microbiology (ASM) MICROBE 2018. Atlanta, GA; 2018."},{"key":"1688_CR18","unstructured":"Zhanel GG, Adam H, Baxter M, Denisuik A, Lagace-Wiens P, Walkty A, et al. In vitro activity of sulopenem, an oral penem, against Escherichia coli isolated from urine specimens of patients across Canada in 2014-2016 [abstract plus poster SUNDAY-568]. American Society for Microbiology (ASM) MICROBE 2018. Atlanta, GA; 2018."},{"key":"1688_CR19","unstructured":"Dunne M, Puttagunta S, Fisher J, Koeth L. In vitro activity of sulopenem against resistant Neisseria gonorrhoeae [abstract plus poster P1705]. In: 29th European Congress of Clinical Microbiology & Infectious Diseases. Amsterdam; 2019."},{"key":"1688_CR20","unstructured":"Puttagunta S, Dunne M. Antimicrobial activity of sulopenem tested against Gram-positive and Gram-negative organisms from the United States and Europe (2013-2015) [abstract plus poster]. American Society for Microbiology (ASM) MICROBE 2017. New Orleans, LA; 2017."},{"key":"1688_CR21","unstructured":"Aronin SI, Huband M, Flamm R, Puttagunta S, Dunne M. Sulopenem activity against Enterobacteriaceae isolates from patients with urinary tract infection [abstract plus poster]. American Society for Microbiology (ASM) MICROBE 2018. Atlanta, GA; 2018."},{"key":"1688_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7164\/antibiotics.49.366","volume":"49","author":"K Watanabe","year":"1996","unstructured":"Watanabe K, Kato N, Tanaka K, Tanaka Y, Kato H, Ueno K. In vitro activities of sulopenem, a new parenteral penem, against anaerobes. Jpn J Antibiot. 1996;49:367\u201376.","journal-title":"Jpn J Antibiot"},{"key":"1688_CR23","first-page":"352","volume":"49","author":"A Komoto","year":"1996","unstructured":"Komoto A, Otsuki M, Nishino T. In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic. Jpn J Antibiot. 1996;49:352\u201366.","journal-title":"Jpn J Antibiot"},{"key":"1688_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7164\/antibiotics.49.45","volume":"49","author":"E Inoue","year":"1996","unstructured":"Inoue E, Komoto E, Taniyama Y, Mitsuhashi S. Antibacterial activity of sulopenem, a new parenteral penem antibiotic. Jpn J Antibiot. 1996;49:338\u201351.","journal-title":"Jpn J Antibiot"},{"key":"1688_CR25","first-page":"324","volume":"49","author":"T Yoshida","year":"1996","unstructured":"Yoshida T, Tateda E, Hiramatsu K, Yokota T. In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996;49:324\u201337.","journal-title":"Jpn J Antibiot"},{"key":"1688_CR26","first-page":"303","volume":"49","author":"M Nagashima","year":"1996","unstructured":"Nagashima M, Goto S, Yoshida T, Matsunaga T, Shimohira H, Ogawa M. In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins. Jpn J Antibiot. 1996;49:303\u201323.","journal-title":"Jpn J Antibiot"},{"key":"1688_CR27","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1021\/op300131e","volume":"16","author":"SJ Brenek","year":"2012","unstructured":"Brenek SJ, Caron S, Chisowa E, Delude MP, Drexler MT, Ewing MD, et al. Development of a practical and convergent process for the preparation of sulopenem. Org Process Res Dev Am Chem Soc. 2012;16:1348\u201359.","journal-title":"Org Process Res Dev Am Chem Soc"},{"key":"1688_CR28","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1021\/op300130p","volume":"16","author":"SJ Brenek","year":"2012","unstructured":"Brenek SJ, Caron S, Chisowa E, Colon-Cruz R, Delude MP, Drexler MT, et al. Development of a second-generation process to antibacterial candidate sulopenem. Org Process Res Dev Am Chem Soc. 2012;16:1338\u201347.","journal-title":"Org Process Res Dev Am Chem Soc"},{"key":"1688_CR29","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1128\/AAC.49.7.2941-2948.2005","volume":"49","author":"K Hujer","year":"2005","unstructured":"Hujer K, Hamza N, Hujer A, Perez F, Helfand M, Bethel C, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother. 2005;49:2941\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR30","unstructured":"Zhanel GG, Adam HJ, Baxter MR, Golden A, Lagac\u00e9-Wiens P, Walkty A, et al. In vitro activity of sulopenem and comparative agents against bacterial pathogens isolated from Canadian patients with urinary tract infections: CANWARD surveillance study 2014-2020 [abstract no. 4674 plus poster]. World Microbe Forum. Online Worldwide; 2021."},{"key":"1688_CR31","doi-asserted-by":"crossref","unstructured":"Dunne M, Aronin S, Dunzo E, Puttagunta S. A phase 1, randomized, open-label, crossover study in healthy subjects under fasting conditions of orally administered sulopenem etzadroxil alone or with probenecid to determine the pharmacokinetics of sulopenem [abstract plus poster]. IDWeek 2018. San Francisco, CA; 2018.","DOI":"10.1093\/ofid\/ofy210.1224"},{"key":"1688_CR32","doi-asserted-by":"crossref","unstructured":"Dunne M, Dunzo E, Puttagunta S. A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270) [abstract plus poster]. IDWeek 2017. San Diego, CA; 2017.","DOI":"10.1093\/ofid\/ofx163.1369"},{"key":"1688_CR33","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1128\/AAC.45.7.1964-1971.2001","volume":"45","author":"K Okamoto","year":"2001","unstructured":"Okamoto K, Gotoh N, Nishino T. Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: Penem resistance mechanisms and their interplay. Antimicrob Agents Chemother. 2001;45:1964\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR34","unstructured":"Dunne M, Puttagunta S, Aronin S, Huband M, Flamm R. Post-antibiotic and sub-inhibitory minimum inhibitory concentration effects of sulopenem [abstract plus poster P1992]. In: 29th European Congress of Clinical Microbiology & Infectious Diseases. Amsterdam; 2019."},{"key":"1688_CR35","unstructured":"Dunne M, Morrissey I, de Piano C, Magnet S, Hawser S, Puttagunta S. Antimicrobial activity of sulopenem in the urine of healthy volunteers [abstract plus poster]. In: 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid; 2018."},{"key":"1688_CR36","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1128\/AAC.01531-08","volume":"53","author":"K Kosowska-Shick","year":"2009","unstructured":"Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC. Comparative antipneumococcal activities of sulopenem and other drugs. Antimicrob Agents Chemother. 2009;53:2239\u201347.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR37","doi-asserted-by":"crossref","unstructured":"Puttagunta S, Aronin S, Huband M, Flamm R, Dunne M. Sulopenem activity against Enterobacteriaceae isolates from patients with urinary tract infection or intra-abdominal infection [abstract plus poster]. IDWeek 2018. San Francisco, CA; 2018.","DOI":"10.1093\/ofid\/ofy210.1194"},{"key":"1688_CR38","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1128\/AAC.37.7.1547","volume":"37","author":"M Minamimura","year":"1993","unstructured":"Minamimura M, Taniyama Y, Inoue E, Mitsuhashi S. In vitro antibacterial activity and \u03b2-lactamase stability of CP-70,429, a new penem antibiotic. Antimicrob Agents Chemother. 1993;37:1547\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7164\/antibiotics.43.422","volume":"43","author":"T Gootz","year":"1990","unstructured":"Gootz T, Girard D, Schelkley W, Tensfeldt T, Foulds G, Kellogg M, et al. Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester. J Antibiot. 1990;43:422\u201332.","journal-title":"J Antibiot"},{"key":"1688_CR40","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1592\/phco.23.14.1497.31937","volume":"23","author":"JMT Hamilton-Miller","year":"2003","unstructured":"Hamilton-Miller JMT. Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem. Pharmacotherapy. 2003;23:1497\u2013507.","journal-title":"Pharmacotherapy"},{"key":"1688_CR41","doi-asserted-by":"publisher","first-page":"e0055221","DOI":"10.1128\/AAC.00552-21","volume":"65","author":"CL Chatwin","year":"2021","unstructured":"Chatwin CL, Hamrick JC, Trout REL, Myers CL, Cusick SM, Weiss WJ, et al. Microbiological characterization of VNRX-5236, a broad-spectrum \u03b2-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended-spectrum \u03b2-lactamases and serine carbapenemases. Antimicrob Agents Chemother. 2021;65:e0055221.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1128\/AAC.35.4.665","volume":"35","author":"G Foulds","year":"1991","unstructured":"Foulds G, Knirsch AK, Lazar JD, Tensfeldt TG, Gerber N. Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans. Antimicrob Agents Chemother. 1991;35:665\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR43","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1128\/AAC.33.8.1160","volume":"33","author":"T Gootz","year":"1989","unstructured":"Gootz T, Retsema J, Girard A, Hamanaka E, Anderson M, Sokolowski S. In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother. 1989;33:1160.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR44","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1128\/AAC.00285-06","volume":"50","author":"FM Kaczmarek","year":"2006","unstructured":"Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of blaACT-1 \u03b2-lactamase production, porin OmpK35\/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE. Antimicrob Agents Chemother. 2006;50:3396\u2013406.","journal-title":"Antimicrob Agents Chemother"},{"key":"1688_CR45","unstructured":"Iterum Therapeutics. Iterum Therapeutics announces topline results from phase 3 clinical trial of oral and IV sulopenem for the treatment of complicated intra-abdominal infections. 2019. https:\/\/www.iterumtx.com\/news\/press-releases\/detail\/29\/iterum-therapeutics-announces-topline-results-from-phase-3. Accessed 11 Jul 2021."},{"key":"1688_CR46","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","volume":"18","author":"U Theuretzbacher","year":"2020","unstructured":"Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH, Tacconelli E, et al. Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol. 2020;18:286\u201398.","journal-title":"Nat Rev Microbiol"},{"key":"1688_CR47","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1517\/13543776.2010.515588","volume":"20","author":"K Bush","year":"2010","unstructured":"Bush K, Macielag M. New \u03b2-lactam antibiotics and \u03b2-lactamase inhibitors. Expert Opin Ther Pat. 2010;20:1277\u201393.","journal-title":"Expert Opin Ther Pat"},{"key":"1688_CR48","unstructured":"Huband MD, Gootz TD, Mullins LM, McCurdy SP, Brennan LA, Penzien JB, et al. In vitro antibacterial activity of sulopenem: a new oral penem antimicrobial versus recent bacterial clinical isolates [abstract plus poster F1-344]. In: 48th Annual ICAAC\/IDSA 46th Annual Meeting. Washington, DC; 2008."},{"key":"1688_CR49","unstructured":"Girard D, Finegan S, O\u2019Donnell JP. Pharmacokinetics and pharmacodynamics of sulopenem in preclinical species [abstract plus poster A-054]. In: 48th Annual ICAAC\/IDSA 46th Annual Meeting. Washington, DC; 2008."},{"key":"1688_CR50","unstructured":"Forrest A, Hazra A, Girard D, O\u2019Donnell J, Hanna D, Ogden A, et al. PK\/PD analysis to select IV sulopenem and oral PF-03709270 doses for phase 2 trials (abstract plus poster A-034). In: 48th Annual ICAAC\/IDSA 46th Annual Meeting. Washington, DC; 2008."},{"key":"1688_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/14787210.5.2.185","volume":"5","author":"KN Schurek","year":"2007","unstructured":"Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007;5:185\u201398.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1688_CR52","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.bcp.2005.12.003","volume":"71","author":"A Dalhoff","year":"2006","unstructured":"Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem Pharmacol. 2006;71:1085\u201395.","journal-title":"Biochem Pharmacol"},{"key":"1688_CR53","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs. 2007;67:1027\u201352.","journal-title":"Drugs"},{"key":"1688_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1586\/14787210.3.1.23","volume":"3","author":"GG Zhanel","year":"2005","unstructured":"Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther. 2005;3:23\u201339.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1688_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"G Zhanel","year":"2018","unstructured":"Zhanel G, Lawrence C, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem\u2013relebactam and meropenem\u2013vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations. Drugs. 2018;78:65\u201398.","journal-title":"Drugs"},{"issue":"Suppl 4","key":"1688_CR56","doi-asserted-by":"publisher","first-page":"vi5","DOI":"10.1093\/jac\/dkz283","volume":"74","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, et al. 42936 pathogens from Canadian hospitals: 10 years of results (2007\u201316) from the CANWARD surveillance study. J Antimicrob Chemother. 2019;74(Suppl 4):vi5-21.","journal-title":"J Antimicrob Chemother"},{"key":"1688_CR57","first-page":"215","volume":"9","author":"GG Zhanel","year":"1998","unstructured":"Zhanel GG, Simor AE, Vercaigne L, Mandell L. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis. 1998;9:215\u201328.","journal-title":"Can J Infect Dis"},{"key":"1688_CR58","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1038\/clpt.2010.270","volume":"89","author":"A Hazra-Raybon","year":"2011","unstructured":"Hazra-Raybon A, O\u2019Gorman M, Puttagunta S, Soma K, Skogerboe T, Fang J, et al. Effect of various degrees of renal impairment (RI) on the pharmacokinetics (PK) of sulopenem after IV and oral administration [abstract]. Clin Pharmacol Ther. 2011;89:S26.","journal-title":"Clin Pharmacol Ther"},{"key":"1688_CR59","unstructured":"Iterum Therapeutics. Iterum Therapeutics announces topline results from its phase 3 clinical trial of oral sulopenem for the treatment of uncomplicated urinary tract infections. 2020. https:\/\/www.iterumtx.com\/news\/press-releases\/detail\/40\/iterum-therapeutics-announces-topline-results-from-its. Accessed 5 Aug 2021."},{"key":"1688_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","volume":"12","author":"N Robbins","year":"2011","unstructured":"Robbins N, Koch SE, Tranter M, Rubinstein J. The history and future of probenecid. Cardiovasc Toxicol. 2011;12:1\u20139.","journal-title":"Cardiovasc Toxicol"},{"key":"1688_CR61","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","volume":"38","author":"C-C Wu","year":"2016","unstructured":"Wu C-C, Pai T-Y, Hsiao F-Y, Shen L-J, Wu F-LL. The effect of different carbapenem antibiotics (ertapenem, imipenem\/cilastatin, and meropenem) on serum valproic acid concentrations. Ther Drug Monit. 2016;38:587\u201392.","journal-title":"Ther Drug Monit"},{"key":"1688_CR62","unstructured":"A study to investigate the pharmacokinetics, safety and tolerability of an intravenous and oral form of a compound in subjects with varying degrees of renal impairment and normal renal function\u2014study results. ClinicalTrials.gov; 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00759564?cond=NCT00759564&draw=2&rank=1&view=results. Accessed 6 Sep 2021."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01688-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01688-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01688-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T08:11:35Z","timestamp":1650355895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01688-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01688-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"13 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"George G. Zhanel has received research grants from Iterum Pharmaceuticals. Marianna Pozdirca, Alyssa Golden, Courtney K. Lawrence, Sheryl Zelenitsky, Liam Berry, Frank Schweizer, Denice Bay, Heather J. Adam, Michael A. Zhanel, Philippe Lagac\u00e9-Wiens, Andrew Walkty, Neal Irfan, Kurt Naber, Joseph P. Lynch III and James A. Karlowsky have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The authors are grateful to Iterum Pharmaceuticals for their assistance with literature retrieval and an unrestricted research grant to aid in funding Marianna Pozdirca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"GGZ: design and concept of the entire manuscript and drafting all sections; senior and corresponding author. MP: design and concept of the entire manuscript and drafting all sections. AG: design and concept of the entire manuscript and drafting all sections. CKL: design and concept of the entire manuscript and drafting the Pharmacokinetic\/Pharmacodynamic section. SZ: design and concept of the entire manuscript and drafting the Pharmacokinetic\/Pharmacodynamic section. LB: design and concept of the entire manuscript and drafting the Chemistry and Microbiology sections. FS: design and concept of the entire manuscript and drafting the Chemistry and Microbiology sections. DB: design and concept of the entire manuscript and drafting the Introduction, Mechanisms of Action and Mechanisms of Resistance sections. HJA: design and concept of the entire manuscript and drafting the Microbiology section. MAZ: design and concept of the entire manuscript and drafting the Introduction, Mechanisms of Action, Mechanisms of Resistance, Chemistry and Microbiology sections. PL-W: design and concept of the entire manuscript and drafting the Animal Models section. AW: design and concept of the entire manuscript and drafting the Clinical Trials, Adverse Effects and Place in Therapy sections. NI: design and concept of the entire manuscript and drafting the Adverse Effects, Drug Interactions and Place in Therapy sections. KN: design and concept of the entire manuscript and drafting the Clinical Trials section. JPLIII: design and concept of the entire manuscript and drafting the Clinical Trials and Place in Therapy sections. JAK: design and concept of the entire manuscript and drafting all sections.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}